A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort

CONCLUSIONS: Long-term efficacy and safety results in the Taiwan cohort are consistent with those in the global cohort.PMID:38044204 | DOI:10.1016/j.jfma.2023.10.016

Source: J Formos Med Assoc - December 3, 2023 Category: General Medicine Authors: Ming-Jen Lee Hung-Chou Kuo Lin-Na Chou Marianne T Sweetser Jiaan-Der Wang Source Type: research